MARKET

GLPG

GLPG

Galapagos
NASDAQ

Real-time Quotes | Nasdaq Last Sale

82.77
-2.11
-2.49%
Opening 14:26 03/05 EST
OPEN
83.70
PREV CLOSE
84.88
HIGH
83.70
LOW
82.26
VOLUME
204.64K
TURNOVER
--
52 WEEK HIGH
233.14
52 WEEK LOW
81.37
MARKET CAP
5.41B
P/E (TTM)
-14.1904
1D
5D
1M
3M
1Y
5Y
Maxim Group Maintains Their Hold Rating on Galapagos (GLPG)
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Hold rating on Galapagos (GLPG). The company's shares closed last Friday at
SmarterAnalyst · 4h ago
Galapagos' Filgotinib Shows Interim Safety In Ongoing Studies
Galapagos NV (NASDAQ: GLPG) has announced 
Benzinga · 1d ago
The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 3)
Benzinga · 1d ago
Galapagos (GLPG) Receives a Hold from Stifel Nicolaus
In a report released today, Derek Archila from Stifel Nicolaus reiterated a Hold rating on Galapagos (GLPG). The company's shares closed last Wednesday at
SmarterAnalyst · 1d ago
Pulmonary Fibrosis Drug Market Is Estimated To Grow With A CAGR of 12.9% from 2020-2026
Mar 04, 2021 (Market Insight Reports) -- A recent report provides crucial insights along with application based and forecast information in the Global...
Market Insight Reports · 1d ago
European markets pull back as bond moves wobble global stocks
European markets retreated Thursday as a rise in a bond yields saw jitters return to global stocks once again.
CNBC.com · 1d ago
Galapagos reports interim filgotinib data from MANTA AND MANTA-RAy studies
Galapagos (GLPG) announces interim results from MANTA and MANTA-RAy, two ongoing safety studies investigating the effect of Jyseleca (filgotinib) on sperm parameters in males with inflammatory bowel disease ((MANTA)) or rheumatic
Seekingalpha · 1d ago
BRIEF-Galapagos Reports Primary Endpoint For Ongoing Filgotinib Manta, Manta-Ray Safety Studies
reuters.com · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GLPG. Analyze the recent business situations of Galapagos through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GLPG stock price target is 94.05 with a high estimate of 126.94 and a low estimate of 75.77.
EPS
Institutional Holdings
Institutions: 237
Institutional Holdings: 6.39M
% Owned: 9.76%
Shares Outstanding: 65.41M
TypeInstitutionsShares
Increased
41
1.46M
New
58
-2.51M
Decreased
35
1.80M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.05%
Pharmaceuticals & Medical Research
+0.47%
Key Executives
Chairman - Management/Chief Executive Officer/Executive Director
Onno van de Stolpe
Non-Executive Chairman
Raj Parekh
Non-Executive Chairman
Rajesh Parekh
Chief Financial Officer/Chief Operating Officer/Executive Board
Bart Filius
Chief Scientific Officer/Executive Board
Piet Wigerinck
Executive Board
Walid Abi-Saab
Vice President/IR Contact Officer
Elizabeth Goodwin
Executive Board
Andre Hoekema
Non-Executive Independent Director
Katrine Bosley
Non-Executive Director
Harrold van Barlingen
Non-Executive Independent Director
Werner Cautreels
Non-Executive Independent Director
Mary Kerr
Non-Executive Independent Director
Christine Mummery
No Data
About GLPG
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.

Webull offers kinds of Galapagos NV stock information, including NASDAQ:GLPG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLPG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GLPG stock methods without spending real money on the virtual paper trading platform.